Table 1.
Baseline characteristics of the primary analytic sample
| PVC cohort (n = 820) | Controls (n = 3 264) | P | SMD | |
|---|---|---|---|---|
| Age, median (IQR) | 59.0 (45.0–70.0) | 59.0 (45.0–70.0) | 0.983 | <0.001 |
| Men, n (%) | 347 (42.3) | 1376 (42.2) | 0.965 | 0.003 |
| Ischaemic heart disease, n (%) | 0 (0.0) | 155 (4.7) | <0.001 | 0.316 |
| Heart failure, n (%) | 0 (0.0) | 60 (1.8) | <0.001 | 0.194 |
| Cancer, n (%) | 112 (13.7) | 317 (9.7) | 0.001 | 0.123 |
| Hypertension, n (%) | 173 (21.1) | 535 (16.4) | 0.002 | 0.121 |
| Diabetes, n (%) | 39 (4.8) | 212 (6.5) | 0.076 | 0.076 |
| Cerebrovascular disease, n (%) | 23 (2.8) | 128 (3.9) | 0.158 | 0.062 |
| Hyperlipidaemia, n (%) | 66 (8.0) | 161 (4.9) | 0.001 | 0.127 |
| Atrial fibrillation, n (%) | 50 (6.1) | 137 (4.2) | 0.025 | 0.086 |
| Beta blockers, n (%) | 410 (50.0) | 760 (23.3) | <0.001 | 0.577 |
| Anticoagulants and platelet inhibitors, n (%) | 238 (29.0) | 752 (23.0) | <0.001 | 0.137 |
| Antiarrhythmic drug, class 1, n (%) | 14 (1.7) | 9 (0.3) | <0.001 | 0.145 |
| Antiarrhythmic drug, class 3, n (%) | 11 (1.3) | 3 (0.1) | <0.001 | 0.149 |
| Calcium channel blockers, n (%) | 216 (26.3) | 611 (18.7) | <0.001 | 0.183 |
| Diuretics, n (%) | 311 (37.9) | 983 (30.1) | <0.001 | 0.165 |
| Digitalis, n (%) | 6 (0.7) | 27 (0.8) | 0.956 | 0.011 |
| ACE inhibitors, n (%) | 159 (19.4) | 602 (18.4) | 0.567 | 0.024 |
| Angiotensin receptor blockers, n (%) | 108 (13.2) | 401 (12.3) | 0.531 | 0.027 |